

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO Box 1430 Alexandria, Virginia 22313-1450 www.tepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/586,772	02/15/2007	Peter Schofield	FBRIC54.003APC	4743	
20905 OUISCOOP SEARCH SEAR LLP 2040 MAIN STREET FOURTEENTH FLOOR IRVINE. CA 92614			EXAM	EXAMINER	
			MYERS,	MYERS, CARLA J	
			ART UNIT	PAPER NUMBER	
		1634			
			NOTIFICATION DATE	DELIVERY MODE	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

jcartee@kmob.com eOAPilot@kmob.com

Application No. Applicant(s) 10/586,772 SCHOFIELD ET AL. Office Action Summary Examiner Art Unit Carla Myers 1634 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status Responsive to communication(s) filed on 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1.3.4.6.13.18-21.24.25.34.36-40.42 and 43 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) _____ is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1, 3, 4, 6, 13, 18-21, 24, 25, 34, 36-40, 42, and 43 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date. Notice of Draftsperson's Patent Drawing Review (PTO-948)

Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date ______.

5) Notice of Informal Patent Application

6) Other:

Page 2

Application/Control Number: 10/586,772

Art Unit: 1634

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1, 3, 4, 6, 13, 18-21, 25, 36 and 37 (in part), drawn to nucleic acid based methods for determining a bipolar affective disorder by assaying for a nucleic acid marker.

Group II, claims 1, 3, 4, 6, 13, 24, 25, 36 and 37 (in part), drawn to protein-based methods for determining a bipolar affective disorder by assaying for a protein marker.

Group III, claim 34, drawn to a probe or primer comprising at least about 20 nucleotides and capable of detecting a marker in a FAT gene.

Group IV, claim 38, drawn to methods of identifying a new marker that is associated with a bipolar affective disorder.

Group V, claims 39 and 42, drawn to a method for determining a candidate compound for treating a bipolar affective disorder by administering a compound to an animal or cell that expresses a marker for a FAT gene and an animal or cell that does not express a marker with a FAT gene.

Group VI, claim 40, drawn to a method for determining a candidate compound for treatment of a bipolar affective disorder comprising determining a level of

Application/Control Number: 10/586,772

Art Unit: 1634

expression of a FAT gene in an animal or cell treated with a compound and comparing this level to that of an animal or cell that is not treated with said compound.

Group VII, claim 43, drawn to a process of manufacturing a compound.

2. The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature for the following reasons:

A 371 case is considered to have unity of invention only when there is a technical relationship among those inventions involving one or more of the same or corresponding technical features. The expression "special technical feature" means those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art. In the instant application, different inventions are linked by the technical feature of the FAT gene, which is present within the region of 4g35.2. However, the FAT gene present at chromosome 4g35.2 was known in the art at the time the invention was made. In particular, Dunne (Genomics. 1995. 30: 207-223) teaches the cloning of and the nucleotide and amino acid sequence of the FAT gene. The FAT gene and probes of the FAT gene disclosed by Dunne comprise at least 20 nucleotides of SEQ ID NO: 1 and can be used to detect markers in the FAT gene, as is required by present claim 34. Further, regarding claims 1 and 3, the prior art teaches methods for determining a bipolar affective disorder by assaying for a marker linked to map position 4q35.2 since the prior art of Adams, Blair and Badenhop (cited in the IDS) each teaches markers within the 4q35 chromosomal region, including

Application/Control Number: 10/586,772

Art Unit: 1634

4q35.2, which are linked to bipolar affective disorder. Since the technical feature linking the claimed inventions was known in the art at the time the invention was made, there is no special technical feature linking the recited groups, as would be necessary to fulfill the requirement for unity of invention.

Additionally, groups I, II and IV-VII are drawn to distinct methods. Each method requires performing different active process steps, requires the use of different reagents and has a different mode of action and effect. As such, each of the methods has a different objective and outcome and do not share a corresponding technical feature.

- 3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 4. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Application/Control Number: 10/586,772

Art Unit: 1634

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently

found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carla Myers whose telephone number is 571-272-0747. The examiner can normally be reached on Monday-Thursday (6:30-5:00).

in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Art Unit: 1634

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Carla Myers/

Primary Examiner, Art Unit 1634